This appraisal of nivolumab was to have been discussed at the Technology Appraisal Committee meeting on 4 August. This discussion will not take place.
NICE has recently been informed that the company wishes to submit additional cost-effectiveness modelling, including a Patient Access Scheme, in response to the ACD. The Patient Access Scheme has not yet been approved. An independent critique of the new modelling is also needed before the Committee can discuss the appraisal. This discussion will therefore take place on 7 September to enable this critique to be completed and the Patient Access Scheme to be considered.